NKEM NWAOBI: Open Payments
NPI 1659897130 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$840 in 12 payments from 7 companies in 2025. Trend: 2023 $705 · 2024 $688 · 2025 $840
Food & beverage: $840
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $233 |
| ABBVIE INC. | 2 | $178 |
| Axsome Therapeutics, Inc. | 2 | $139 |
| Gilead Sciences, Inc. | 1 | $92 |
| MIMEDX Group, Inc. | 1 | $91 |
| E.R. Squibb & Sons, L.L.C. | 1 | $85 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
Products named: CAPLYTA, VRAYLAR, Auvelity, Livdelzi, COBENFY, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
